Get notified when VKTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Auditor Change (new) — The company changed its independent auditor from Marcum LLP to CBIZ CPAs P.C. for the 2025 fiscal year, which may warrant investor attention.
Viking Therapeutics offers $225M convertible notes and 7.86M common shares; net proceeds $218M
Filed September 25, 2026 · ~1 min read
Key Changes
-
high
Viking is offering $225M of 2.00% convertible senior notes due 2032, with an initial conversion price of about $50.75 per share, a premium to the last sale of $40.85.
The Offering verify on EDGAR → -
high
Concurrently, the company is offering 7,857,143 common shares, with an over-allotment option for 1,178,571 more. The two offerings are not contingent on each other.
The Offering verify on EDGAR → -
high
Net proceeds to the company are estimated at $218.0M ($250.8M if over-allotment fully exercised), after underwriting discounts and expenses.
Use of Proceeds verify on EDGAR →
4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade VKTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 25, 2026 · How we verify